A81.2
Progressive multifocal leukoencephalopathy
Clinical Classification Guidelines
Inclusion Terms
- Multifocal leukoencephalopathy NOS
Medical Intelligence & Overview
Progressive multifocal leukoencephalopathy (PML) is a rare, often serious brain disorder caused by the JC virus. It affects the white matter of the brain, leading to neurological impairment. The condition primarily occurs in individuals with weakened immune systems, such as those with HIV/AIDS, certain cancers, or recipients of organ transplants. PML is characterized by the gradual deterioration of nerve fibers in multiple areas of the brain, which impairs communication between different parts of the brain and the rest of the body. Early diagnosis and management are crucial to slowing the progression of the disease and improving quality of life.
Causes & Symptoms
Clinical Causes: Reactivation of the JC virus in individuals with compromised immune defenses HIV/AIDS leading to weakened immune system Use of immunosuppressive medications for autoimmune diseases or post-transplant care Certain types of cancer or cancer treatments that suppress immune function Other conditions causing immune suppression that allow JC virus proliferation
Key Symptoms: Weakness or paralysis on one side of the body Problems with coordination and balance Difficulty speaking or understanding speech Changes in vision, such as blurred vision or partial loss Clumsiness or difficulty walking Alterations in mental state, including confusion or memory issues Headaches or seizures in some cases Progressive worsening of neurological functions over weeks to months
Diagnostic & Treatment
Diagnosis Path: Diagnosis of PML involves a combination of clinical assessment and diagnostic tests. These may include neuroimaging techniques like MRI scans revealing characteristic areas of white matter damage, cerebrospinal fluid analysis for JC virus DNA detection through polymerase chain reaction (PCR), and ruling out other neurological conditions. Patient history and symptom progression also aid in diagnosis.
Treatment Protocols: There is currently no specific antiviral treatment for PML. Management focuses on restoring immune function where possible, such as optimizing antiretroviral therapy in HIV-positive individuals. Reducing or discontinuing immunosuppressive treatments might be considered under medical supervision. Supportive care, including physical therapy and symptomatic treatment for neurological deficits, can improve quality of life. Ongoing research continues to explore potential therapies for this condition.
Clinical Advice & FAQs
Billing Guidance
Is A81.2 a billable ICD-10 code?
Yes, A81.2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report A81.2?
Clinical documentation must specify the nature of Progressive multifocal leukoencephalopathy and any associated comorbidities for accurate reporting.
Cite this Clinical Reference